HGH is a master hormone protein responsible for growth stimulation, development and regeneration of healthy cells. Deficiency of growth hormone leads to Growth Hormone Deficiency (GHD), which is a chronic disease affecting both children and adults. The report ?Global Human Growth Hormone (HGH) Market Outlook 2022? provides an in-depth analysis of global HGH market, focusing on Pediatric and Adult GHD.

The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities at the global and regional level. The report has been segmented as following:-

Market Segmentation
? Paediatric GHD
? Adult GHD
? Other Disorders
Market Segmentation by Geography
? Europe
? North America-The US
? Asia Pacific-Japan
Key Vendors
? Merck Serono
? Novo Nordisk
? Pfizer
? Eli Lilly
? F. Hoffmann-La Roche Ltd.

Human Growth Hormone (HGH) or Somatotropin is a naturally occurring polypeptide hormone that is synthesized and secreted by the anterior pituitary gland. It is largest protein in the human body made up of a chain of 191 amino acids. HGH is a unique and vital hormone protein, stimulating the growth, development and regeneration of healthy cells throughout the human body. Secretion of HGH into the bloodstream increases throughout childhood, peaks during adolescence, and steadily declines with ageing. Regulation of GH secretion is done by hypothalamus and the mediators of GH actions with major factors including GH releasing hormone (GHRH), somatostatin (SRIF), GH releasing peptide (ghrerin) and insulin-like growth factor (IGF-I). Several other factors such as stress, puberty, obesity, and a variety of signalling molecules also modulate GH release.
Owing to growth stimulating properties of HGH, excessive secretion leads to acromegalic gigantism; while deficiency of GH leads to Growth Hormone Deficiency (GHD), which is a chronic disease affecting both children and adults. GHD in children is characterized by reduced growth performance and a loss of height in comparison to peers. GHD during adulthood manifests symptoms like weight gain, reduced energy levels, disturbed sleep, etc. Standard therapies for treatment of GHD includes administration of recombinant human growth hormone through injections, releasers, sprays, etc.
Growth of the global Human Growth Hormone market is driven by increase in prevalence of pituitary dysfunction, growing geriatric population, high market opportunity due to lower rHGH market penetration across nations, rising healthcare expenditure and affordability. Major factors restraining growth of the market are high treatment cost of rHGH, adverse side-effects of synthetic HGH, illicit use of HGH, poor adherence to therapy by patients and stringent regulatory approvals involved.
In the report, human growth hormone market assessment is done across major markets such as Europe, The US and Japan. The US is the world?s largest HGH market accounting for more than one-third of global HGH market value. In-depth analysis of HGH therapy in aforementioned regions is done on the basis of overall HGH market value as well as pediatric HGH market.

Global human growth hormone therapy industry is highly consolidated with three major players - Novo Nordisk, Pfizer and Eli Lilly and Company dominating the market. These industry players as well as other leading players such as Merck KGaA and Roche are profiled herein based on attributes such as business overview, product segments, financial and business strategies. The report also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global HGH therapy market.
?